Navigation Links
Erlotinib dose-adjusted for smoking status effective as first treatment for head and neck cancer
Date:1/26/2012

Head and neck cancers respond well to the anti-cancer drug erlotinib when it is administered before surgery and a stronger dose is given to patients who smoke, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

Erlotinib is an oral anti-cancer drug that can slow a tumor's growth and spread by inhibiting specific growth receptors on the surface of the cancer cells. Early detection of a patient's response to EGFR inhibitors, such as erlotinib, is critical to personalizing head and neck cancer treatments.

In a first of its kind study in patients with head and neck cancer, researchers sought to determine how well tumors unaffected by other therapies respond to erlotinib, when the drug dose was adjusted according to the patient's smoking status. It has been recently shown that smokers metabolize the drug faster than nonsmokers.

Nonsmokers received 150 mg per day and smokers received 300 mg per day for at least 14 days before surgery. A FDG-PET scan and neck CT was performed before treatment and at the end of erlotinib administration. In addition, an early FDG-PET was performed after four to six days of treatment.

The results showed that erlotinib is effective as a first line of therapy when the dose is adjusted per smoking status, even when used for a limited duration. Both smokers and nonsmokers tolerated the dose of erlotinib and neither experienced serious adverse effects. The study also showed that the FDG-PET scan taken early can show changes in the standard uptake value and predict a patient's response to erlotinib.

"We hope our results will motivate clinicians to consider and investigate further the use of erlotinib in patients with head and neck cancer and adjust the dose for smoking status," Mercedes Porosnicu, MD, lead author of the study and an assistant professor of internal medicine at Wake Forest Baptist Medical Center in Winston Salem, N.C., said. "We also hope that our study will help better select the patients expected to respond to erlotinib."


'/>"/>
Contact: Nicole Napoli
nicolen@astro.org
703-839-7336
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Blood test may identify lung cancer patients likely to respond to erlotinib
2. TRUST study data confirms safety and efficacy of erlotinib for advanced lung cancer
3. Less toxic combination of erlotinib and bevacizumab is effective non-small cell lung cancer patients
4. PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumors
5. EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
6. New Report: $1 Cigarette Tax Increase Would Raise $418.8 Million for Texas and Cut Youth Smoking
7. New Report: $1 Cigarette Tax Increase Would Raise $18.6 Million for Montana and Cut Youth Smoking
8. New Report: $1 Cigarette Tax Increase Would Raise $24.8 Million for Wyoming and Cut Youth Smoking
9. New Report: $1 Cigarette Tax Increase Would Raise $43.3 Million for Utah and Cut Youth Smoking
10. New Report: $1 Cigarette Tax Increase Would Raise $113.9 Million for Colorado and Cut Youth Smoking
11. New Report: $1 Cigarette Tax Increase Would Raise $65.3 Million for Iowa and Cut Youth Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... SunView Software aims to redefine IT self-service ... engaging and easy to use. Coming off the heels of a successful launch ... plans to roll out new AI-powered self-service enhancements to help organizations implement effective ...
(Date:12/8/2016)... ... 2016 , ... California Senate Bill (SB) 863, signed into law in 2012, ... and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , a ... study, medical payments per claim in California decreased 4 percent in 2013 and then ...
(Date:12/8/2016)... ... 2016 , ... The Dianne Michael Insurance Agency, an Ohio-based ... is embarking on a charity drive with the aim of generating support for ... or neglected senior dogs in the Cincinnati region, and LuvFurMutts volunteers also work ...
(Date:12/8/2016)... ... 08, 2016 , ... Coffey Agencies, a locally owned and ... in the northern Alabama and Georgia regions, is embarking on a charity drive ... has built a network of support and education facilities to develop and provide ...
(Date:12/7/2016)... Kenosha, Wisconsin (PRWEB) , ... December 07, 2016 , ... ... the extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED ... the right amount of light where and when it’s needed. , A ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Research and Markets has announced the ... offering. ... The global chromatography market to grow at a CAGR ... 2016-2020, has been prepared based on an in-depth market analysis with inputs ... prospects over the coming years. The report also includes a discussion of ...
(Date:12/8/2016)... Conn. , Dec. 8, 2016  Boehringer Ingelheim ... 2017 Corporate Equality Index (CEI). This is the ninth ... has been designated as a Best Place to Work ... Foundation, the CEI is a national benchmarking report on ... lesbian, gay, bisexual and transgender (LGBT) employees. ...
(Date:12/8/2016)... 2016  Avelas Biosciences, Inc., a clinical stage ... from diagnosis through treatment, today presented clinical trial ... study in breast cancer patients utilizing investigational drug ... Symposium. Jonathan Unkart , M.D., resident physician ... Health, delivered the presentation titled "Intraoperative tumor detection ...
Breaking Medicine Technology: